BioBlast Pharma to Present Corporate Overview at the 28th Annual ROTH Conference
March 10, 2016 08:00 ET
|
Bioblast Pharma Ltd.
NEW HAVEN, Conn., March 10, 2016 (GLOBE NEWSWIRE) -- BioBlast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced today that Colin Foster,...
BioBlast Pharma Reports Fourth Quarter and Full Year 2015 Financial Results
February 23, 2016 16:05 ET
|
Bioblast Pharma Ltd.
NEW HAVEN, Conn., Feb. 23, 2016 (GLOBE NEWSWIRE) -- BioBlast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announced financial results for the...
BioBlast Pharma Enhances Leadership Team
January 11, 2016 08:00 ET
|
Bioblast Pharma Ltd.
NEW HAVEN, Conn., Jan. 11, 2016 (GLOBE NEWSWIRE) -- BioBlast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage biotechnology company committed to developing meaningful therapies for patients with rare...
BioBlast Pharma Provides Research and Development Update
December 09, 2015 06:00 ET
|
Bioblast Pharma Ltd.
NEW HAVEN, Conn., Dec. 9, 2015 (GLOBE NEWSWIRE) -- BioBlast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage biotechnology company developing meaningful therapies for patients with rare and ultra-rare...
BioBlast Pharma Reports Third Quarter Financial Results
November 17, 2015 08:00 ET
|
Bioblast Pharma Ltd.
NEW HAVEN, Conn., Nov. 17, 2015 (GLOBE NEWSWIRE) -- BioBlast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announced financial results for the third...
BioBlast Pharma Strengthens Leadership Team and Announces Key Organizational Changes
November 16, 2015 08:00 ET
|
Bioblast Pharma Ltd.
Significant Evolution of Senior Leadership Team in 2015
Co-Founders Transition Company to Globally-Experienced Executives
NEW HAVEN, Conn., Nov. 16, 2015 (GLOBE NEWSWIRE) -- BioBlast Pharma Ltd....
BioBlast Pharma Announces Website Availability of Webcast Related to Key Opinion Leader Meeting in Oculopharyngeal Muscular Dystrophy (OPMD)
November 09, 2015 08:00 ET
|
Bioblast Pharma Ltd.
NEW HAVEN, Conn., Nov. 9, 2015 (GLOBE NEWSWIRE) -- BioBlast Pharma Ltd., (Nasdaq:ORPN), a clinical-stage biotechnology company developing meaningful therapies for patients with rare and ultra-rare...
BioBlast Announces Positive Interim Results From HOPEMD Phase 2 Clinical Study of Cabaletta(R) in Oculopharyngeal Muscular Dystrophy (OPMD)
October 27, 2015 06:00 ET
|
Bioblast Pharma Ltd.
NEW HAVEN, Conn. and TEL AVIV, Israel, Oct. 27, 2015 (GLOBE NEWSWIRE) -- BioBlast Pharma Ltd., (Nasdaq:ORPN), a clinical-stage biotechnology company developing meaningful therapies for patients with...
BioBlast to Host Conference Call & Webcast on Tuesday, October 27 to Discuss Interim Results From HOPEMD Phase 2 Clinical Study of Cabaletta(R) in Oculopharyngeal Muscular Dystrophy (OPMD)
October 26, 2015 16:01 ET
|
Bioblast Pharma Ltd.
NEW HAVEN, Conn. and TEL AVIV, Israel, Oct. 26, 2015 (GLOBE NEWSWIRE) -- BioBlast Pharma Ltd., (Nasdaq:ORPN), a clinical-stage biotechnology company developing meaningful therapies for patients with...
BioBlast Pharma Augments Leadership Team
October 09, 2015 08:00 ET
|
Bioblast Pharma Ltd.
NEW HAVEN, Conn., Oct. 9, 2015 (GLOBE NEWSWIRE) -- BioBlast Pharma Ltd., (Nasdaq:ORPN), a clinical-stage biotechnology company committed to developing meaningful therapies for patients with rare and...